If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
136
results.
Updated on
06/05/2025 [07:37:00]
Results 125 to 136 of 136
Absstract of: US2025082762A1
The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.
Absstract of: US2025082647A1
The present invention relates in a first aspect to a compound of formula (I) for use in the treatment and/or in prevention of Alzheimer's dementia, wherein the compound of formula (I) is administered in a dosage<20 mg. In a second aspect, the invention relates to a pharmaceutical composition comprising the compound according to the first aspect.
Absstract of: US2025082686A1
The present disclosure provides adeno-associated vector (AAV)-based methods of increasing gene expression of a GBA1 in floor plate midbrain progenitor cells, determined dopamine (DA) neuron progenitor cells, and/or DA neurons, or glial cells, including those differentiated from pluripotent stem cells, and methods of lineage specific differentiation of the same. Also provided are compositions and uses thereof, such as for treating neurodegenerative diseases and conditions, including Parkinson's disease.
Absstract of: AU2023316187A1
Provided is a drug for treating Alzheimer's disease, the drug enabling retention of cognitive function amelioration and nerve quality improvement for a specific time even after treatment ends. This drug for causal treatment of Alzheimer's disease (disease-modifying drug) contains hydrogen gas as an active ingredient.
Absstract of: AU2023320561A1
Embodiments of the disclosure include methods and compositions related to use of compound comprising a particular peptide linked to a dye. In specific embodiments, the peptide DIRG is linked to the BODIPY dye. In specific embodiments, the compositions are utilized for treatment of neurological conditions and secondary pathologies related therewith, such as spinal cord injury and Alzheimer's Disease, as examples.
Absstract of: AU2023341169A1
The present disclosure provides compounds of Formula I: (I), or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
Absstract of: AU2023347307A1
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Absstract of: US2025084135A1
Fusion protein Tau-4R can be recombined into Escherichia coli to achieve the fusion expression. It is confirmed by means of experiments that the tau protein prepared by the strain may be used in the treatment research of Alzheimer's disease.
Absstract of: AU2023265569A1
The present disclosure relates to the c-Abl inhibitor vodobatinib, or a pharmaceutically acceptable salt thereof, for use in treating, delaying, inhibiting, or suppressing the progression of neurodegenerative diseases, preferably early stage Parkinson's disease, in a subject.
Absstract of: EP4520757A1
The present disclosure relates to an isobenzofuran-1(3H)-one derivative, which is a kinase inhibitor, and a use thereof and, more specifically, to an isobenzofuran-1(3H)-one derivative having HPK1 inhibitory activity and MLK3 inhibitory activity and a pharmaceutical composition containing same for preventing or treating cancer, virus infectious diseases, Parkinson's disease, non-alcoholic steatohepatitis, or tuberculosis. In addition, the compound can be advantageously used as a composition for prevention or treatment of cancer as it is administered in combination with an anticancer agent or a cell therapy product.
Nº publicación: MX2024014831A 07/03/2025
Applicant:
EISAI R&D MAN CO LTD [JP]
EISAI R&D MANAGEMENT CO., LTD
Absstract of: MX2024014831A
Compound of Formula (I)-(V), compositions comprising at least one compound chosen from compounds of Formula (I)-(V), and methods of using the same, including in treatment of Alzheimer's disease.
BOPI
Electronic site
